Cancer-Drug Maker's FDA Data Incited Stock Drop, Suits Say
Clovis Oncology Inc.'s stock price plunged after the drugmaker revealed it gave the U.S. Food and Drug Administration immature clinical trial data when seeking approval for lung cancer drug rociletinib, according...To view the full article, register now.
Already a subscriber? Click here to view full article